BTK Inhibitors
Feb 24, 2026
Gilead Sciences to Acquire Arcellx in Strategic Move to Accelerate Anito-cel Development; Novo Nordisk Faces Setback as CagriSema Underwhelms Against Rival Therapy in Trial; Vanda Pharmaceuticals Secures FDA Approval for BYSANTI; All-oral Calquence + venetoclax Combo Clears in the US for First-line Treatment of CLL; Merck’s ENFLONSIA Demonstrates Strong Protection Against Severe RSV in Young Children Over Consecutive Seasons
Gilead Sciences Announces Acquisition of Arcellx to Advance Long-Term Growth of Anito-cel Gilead Sciences announced a definitive agreement to acquire Arcellx, a clinical-stage biotechnology company, in a strategic move to strengthen its leadership in cell therapy and oncology innovation. The acquisition builds o...
Read More...
Sep 22, 2025
Sanofi’s WAYRILZ Approval Ushers in New Era for Immune Thrombocytopenia Treatment
Immune thrombocytopenia is a rare autoimmune disorder, affecting both children and adults. The global incidence of ITP is estimated at around 2–5 cases per 100,000 people annually, with prevalence higher in adults and a slight female predominance. In 2024, the total cases of immune thrombocytopenia were approxim...
Read More...
Dec 11, 2023
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market
As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly’s Jaypirca. This approval is...
Read More...
Jan 24, 2023
BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy
FDA Approves BeiGene’s Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. SLL is...
Read More...
Aug 28, 2017
Bruton’s Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target
Bruton's Tyrosine Kinase (BTK) is a cytoplasmic member from the Tec (tyrosine kinase expressed in hepatocellular carcinoma) group of kinases which is engaged with controlling the B cell expansion and is essential in B-lymphocyte advancement, separation, and signaling. Bruton's tyrosine kinase; also known as tyrosine...
Read More...
Jul 16, 2015
DelveInsight’s Oncology based Reports, 2015
DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
